NRIX|EPS -$0.79|Rev $6.3M|Net Loss $87.2MNurix Therapeutics, Inc. reported a widening quarterly loss and sharply lower revenue for the first quarter of 2026, highlighting the challenges facing the clinical stage biopharmaceutical company as it advances its pipeline of cancer therapies. The company posted a net loss of $87.2M for the quarter, with a loss per share of $0.79 that widened 17.9% from the $0.67 loss in Q1 2025.
Revenue totaled $6.3M for the quarter, down 66.1% from $18.5M in Q1 2025. The steep revenue decline reflects the variable nature of collaboration and licensing income that typically characterizes early-stage biotechnology companies focused on discovering and developing small molecule and antibody therapies.
Nurix operates in the competitive oncology space, where clinical stage companies often experience significant quarterly fluctuations in collaboration revenue while managing substantial research and development costs. The company continues to advance its pipeline of targeted protein degradation therapies, a novel approach to treating cancer that has attracted significant investor interest across the biotech sector.
Despite the mounting losses, Wall Street analysts maintain a favorable view of the company’s prospects, with consensus standing at 14 buy ratings, 1 hold, and 0 sell recommendations. The strong analyst support suggests confidence in Nurix’s underlying technology platform and clinical programs, even as the company navigates the capital-intensive process of bringing experimental therapies through clinical trials.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.